Shire SWOT Analysis Sample UK

Parent Company: Shire plc

Sector: Pharmaceuticals

USP: One of the world’s leading specialty biopharmaceutical companies

Founded: 1986

Headquarters: Massachusetts, United States

Shire plc is a biopharmaceutical company that focuses on developing and commercializing medicines for rare diseases and other conditions. The company was founded in 1986 and is headquartered in Dublin, Ireland. Shire has approximately 7,500 employees worldwide and is listed on the London Stock Exchange. The company’s products are approved for use in more than 100 countries. In 2018, Shire generated revenue of $15.3 billion. Shire’s mission is to enable people with life-altering conditions to lead better lives. The company strives to meet this goal by investing in research and development, building world-class manufacturing capability, and collaborating with partners around the world who share its commitment to rare diseases and other conditions.

Shire’s product portfolio includes medicines for attention deficit hyperactivity disorder (ADHD), digestive disorders, hereditary angioedema, lysosomal storage disorders, and neurodegenerative disorders. The company’s products are sold in more than 100 countries. In the United States, Shire’s products are marketed under the brand names Adderall, Vyvanse, Intuniv, Lialda, Pentasa, Firazyr, and ELAPRASE.

This was the Shire company overview. Now let’s see the strengths, weaknesses,  opportunities, and threats of Shire plc.

Shire Strengths

1. Strong Product Portfolio: Shire has a strong product portfolio with 7 key products in various therapeutic areas. The company’s flagship product is Vyvanse, which is used to treat ADHD. Other products include Intuniv (used to treat ADHD), Lialda (used to treat Crohn’s disease), Pentasa (used to treat inflammatory bowel disease), and Firazyr (used to treat hereditary angioedema).
2. High Revenue Growth: Shire has a history of high revenue growth. Between 2013 and 2017, the company’s revenue grew from $5.4 billion to $13.6 billion. This represents a compound annual growth rate of 19%.
3. Strong R&D Pipeline: Shire has a strong R&D pipeline with over 60 active clinical programs. The company’s R&D efforts are focused on developing treatments for rare diseases and other conditions.
4. Geographic Diversification: Shire generates revenue from more than 100 countries. In 2018, approximately 60% of the company’s revenue came from the United States, 15% from Europe, and 25% from other countries.
5. High Margins: Shire has high margins. In 2018, the company’s operating margin was 27.5% and its net margin was 22.0%.

Shrine Weaknesses

1. Patent Expirations: Several of Shire’s patents have expired or are set to expire in the next few years. This could lead to increased competition from generic drugmakers and lower revenue for the company.
2. Dependence on Vyvanse: Vyvanse is Shire’s flagship product and generates a significant portion of the company’s revenue. In 2018, Vyvanse accounted for approximately 29% of Shire’s total revenue.
3. Lack of Product Diversity: Shire is heavily dependent on its product portfolio. The company does not have a significant presence in the biologics or vaccines market.
4. High Debt Levels: Shire has high debt levels. As of December 31, 2018, the company had $8.5 billion of debt on its balance sheet.
5. High attrition rate in work force: The company has a high attrition rate in its workforce, which can lead to disruptions in its operations. In 2018, the company’s attrition rate was 23%.

Shrine Opportunities

1. Expansion into Emerging Markets: Shire has significant opportunities for growth in emerging markets. The company’s products are approved for use in more than 100 countries. However, only a small portion of Shire’s revenue is generated from these markets.
2. Acquisitions: Shire has made a number of strategic acquisitions in recent years. In 2016, the company acquired Baxalta for $32 billion. This helped Shire expand its product portfolio and geographic reach.
3. R&D Investment: Shire is investing heavily in R&D. The company’s R&D budget was $2.1 billion in 2018. This represents an increase of 19% from 2017.
4. Partnerships: Shire has partnerships with a number of companies, including Celgene, Pfizer, and Sanofi. These partnerships help the company expand its reach and product portfolio.
5. New customers from online channels: The company has been aggressively marketing its products online. This has helped the company reach new customers and grow its revenue.

Shrine Threat

1. Competition: Shire faces significant competition from other pharmaceutical companies. The company’s products are competing against products from companies such as Pfizer, Novartis, and Merck.
2. Regulatory Risk: Shire’s products are subject to regulation by the FDA and other government agencies. This regulatory risk could lead to delays in product approvals or restrictions on product labeling.
3. Litigation Risk: Shire is facing a number of lawsuits. These lawsuits allege that the company’s products have caused serious side effects.
4. Reputational Risk:  Shire’s reputation has been damaged by a number of scandals. In 2015, the company was fined $350 million by the DOJ for illegally marketing its ADHD drug, Adderall.
5. Financial Risk: Shire is facing a number of financial risks. The company has high debt levels and faces the risk of interest rate hikes.

Pay To Do SWOT Analysis of Shine Plc. At Cheap Prices in UK

Students Assignment Help UK is providing the best assignment writing help in UK for the students who are searching for someone to do their SWOT analysis of Shine plc at cheap prices.

So if you too want your SWOT analysis to be done at low prices then take our help now and get rid of all your worries. Our experienced writers will provide you a top-notch quality assignment before the deadline so that you can score high grades in your exams with our online exam help in UK.

Our marketing assignment writers UK are well aware of all the concepts of marketing and will guide you through the entire process so that you can understand it easily without any difficulty.

They will charge you very nominal amount for providing the best academic writing services with Shine plc SWOT analysis and will make sure to deliver it to you within the deadline. So hurry up and take our assistance now to get rid of all your academic troubles in no time.